Seattle Genetics Inc. has decided to exercise its option to co-develop tisotumab vedotin, an antibody-drug conjugate (ADC) currently in Phase I/II trials for solid tumors, under a six-year-old collaboration with Genmab AS. Both companies will now equally share future costs and profits for the product, giving Seattle rights to commercialize in the US, Canada and Mexico and Genmab the remaining territories.
Under a commercial license and collaboration agreement from Oct. 2011, Genmab was given rights to use Seattle's ADC technology and...